Lipicard Technologies Limited - Product Pipeline Review - 2016

  • ID: 3832314
  • Company Profile
  • 58 pages
  • Global Markets Direct
1 of 4
Lipicard Technologies Limited - Product Pipeline Review - 2016

Summary

‘Lipicard Technologies Limited - Product Pipeline Review - 2016’, provides an overview of the Lipicard Technologies Limited’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Lipicard Technologies Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Lipicard Technologies Limited
- The report provides overview of Lipicard Technologies Limited including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Lipicard Technologies Limited’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Lipicard Technologies Limited’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Lipicard Technologies Limited’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Lipicard Technologies Limited
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lipicard Technologies Limited’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Lipicard Technologies Limited Snapshot

Lipicard Technologies Limited Overview

Key Information

Key Facts

Lipicard Technologies Limited - Research and Development Overview

Key Therapeutic Areas

Lipicard Technologies Limited - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Lipicard Technologies Limited - Pipeline Products Glance

Lipicard Technologies Limited - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

Lipicard Technologies Limited - Drug Profiles

gabafol

Product Description

Mechanism of Action

R&D Progress

KeraKlear

Product Description

Mechanism of Action

R&D Progress

LT-1121

Product Description

Mechanism of Action

R&D Progress

LT-1123

Product Description

Mechanism of Action

R&D Progress

LT-2121

Product Description

Mechanism of Action

R&D Progress

LT-2221

Product Description

Mechanism of Action

R&D Progress

LT-2223

Product Description

Mechanism of Action

R&D Progress

LT-2321

Product Description

Mechanism of Action

R&D Progress

LT-2322

Product Description

Mechanism of Action

R&D Progress

LT-2323

Product Description

Mechanism of Action

R&D Progress

LT-2421

Product Description

Mechanism of Action

R&D Progress

LT-2423

Product Description

Mechanism of Action

R&D Progress

LT-2521

Product Description

Mechanism of Action

R&D Progress

LT-3121

Product Description

Mechanism of Action

R&D Progress

LT-3122

Product Description

Mechanism of Action

R&D Progress

LT-4121

Product Description

Mechanism of Action

R&D Progress

LT-4122

Product Description

Mechanism of Action

R&D Progress

LT-4123

Product Description

Mechanism of Action

R&D Progress

LT-4124

Product Description

Mechanism of Action

R&D Progress

LT-4125

Product Description

Mechanism of Action

R&D Progress

LT-4126

Product Description

Mechanism of Action

R&D Progress

LT-5121

Product Description

Mechanism of Action

R&D Progress

LT-5122

Product Description

Mechanism of Action

R&D Progress

LT-5221

Product Description

Mechanism of Action

R&D Progress

LT-5222

Product Description

Mechanism of Action

R&D Progress

LT-5223

Product Description

Mechanism of Action

R&D Progress

LT-5321

Product Description

Mechanism of Action

R&D Progress

LT-5322

Product Description

Mechanism of Action

R&D Progress

LT-5323

Product Description

Mechanism of Action

R&D Progress

LT-5421

Product Description

Mechanism of Action

R&D Progress

LT-5423

Product Description

Mechanism of Action

R&D Progress

LT-5521

Product Description

Mechanism of Action

R&D Progress

peroxibrate

Product Description

Mechanism of Action

R&D Progress

platrol

Product Description

Mechanism of Action

R&D Progress

raviprofen

Product Description

Mechanism of Action

R&D Progress

LT-6121

Product Description

Mechanism of Action

R&D Progress

Lipicard Technologies Limited - Pipeline Analysis

Lipicard Technologies Limited - Pipeline Products by Target

Lipicard Technologies Limited - Pipeline Products by Route of Administration

Lipicard Technologies Limited - Pipeline Products by Molecule Type

Lipicard Technologies Limited - Pipeline Products by Mechanism of Action

Lipicard Technologies Limited - Locations And Subsidiaries

Head Office

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 58List of Tables

Lipicard Technologies Limited, Key Information

Lipicard Technologies Limited, Key Facts

Lipicard Technologies Limited - Pipeline by Indication, 2016

Lipicard Technologies Limited - Pipeline by Stage of Development, 2016

Lipicard Technologies Limited - Monotherapy Products in Pipeline, 2016

Lipicard Technologies Limited - Preclinical, 2016

Lipicard Technologies Limited - Discovery, 2016

Lipicard Technologies Limited - Pipeline by Target, 2016

Lipicard Technologies Limited - Pipeline by Route of Administration, 2016

Lipicard Technologies Limited - Pipeline by Molecule Type, 2016

Lipicard Technologies Limited - Pipeline Products by Mechanism of Action, 2016 55List of Figures

Lipicard Technologies Limited - Pipeline by Top 10 Indication, 2016

Lipicard Technologies Limited - Pipeline by Stage of Development, 2016

Lipicard Technologies Limited - Monotherapy Products in Pipeline, 2016

Lipicard Technologies Limited - Pipeline by Target, 2016

Lipicard Technologies Limited - Pipeline by Route of Administration, 2016

Lipicard Technologies Limited - Pipeline by Molecule Type, 2016

Lipicard Technologies Limited - Pipeline Products by Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll